Samuele Iesari, Francesca Laura Nava, Ilaria Elena Zais, Laurent Coubeau, Mariano Ferraresso, Evaldo Favi, Jan Lerut
Immunosuppression is essential to ensure recipient and graft survivals after liver transplantation (LT). However, our understanding and management of the immune system remain suboptimal. Current immunosuppressive therapy cannot selectively inhibit the graft-specific immune response and entails a significant risk of serious side effects, i.e., among others, de novo cancers, infections, cardiovascular events, renal failure, metabolic syndrome, and late graft fibrosis, with progressive loss of graft function. Pharmacological research, aimed to develop alternative immunosuppressive agents in LT, is behind other solid-organ transplantation subspecialties, and, therefore, the development of new compounds and strategies should get priority in LT...
March 16, 2024: Hepatobiliary & Pancreatic Diseases International: HBPD INT